Onapristone ER is a Small Molecule owned by Context Therapeutics, and is involved in 14 clinical trials, of which 8 were completed, 5 are ongoing, and 1 is planned.
Onapristone ER (IVV-1001) is an anti-progestin and anti-hormone. Anti-progestin is substance that prevents cells from making or using progesterone. It works by competitively binding to the progesterone receptor, resulting in inhibition of the effects of endogenous or exogenous progesterone. Antiprogestin inhibits the growth of different cancer cell lines with a cytostatic effect in association with a decline in the activity of the cell cycle regulatory protein Cdk2, and apoptotic lethality. Onapristone ER appears to have a unique ability to block the activated progesterone receptor, which is believed to be the mechanism by which it may inhibit the growth of breast and endometrial tumors.
The revenue for Onapristone ER is expected to reach a total of $1.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Onapristone ER NPV Report.
Onapristone ER is currently owned by Context Therapeutics.
Onapristone ER Overview
Onapristone ER (IVV-1001) is under development for the treatment of primary peritoneal cancer, metastatic castration-resistant prostate cancer, endometrial cancer, ER-positive, PgR-positive or negative and HER2-negative locally advanced or metastatic breast cancer and ovarian cancer. The drug candidate is administered through oral route. Onapristone targets progesterone receptor. It is an extended release formulation.
Context Therapeutics Overview
Context Therapeutics is a biopharmaceutical company that is engaged in developing advanced small molecule and immunotherapies for cancer. The company is headquartered in Philadelphia, Pennsylvania, the US.
The operating loss of the company was US$10.4 million in FY2021, compared to an operating loss of US$2.6 million in FY2020. The net loss of the company was US$10.5 million in FY2021, compared to a net profit of US$6.6 million in FY2020.
Quick View – Onapristone ER
|Highest Development Stage|